# Comprehensive Assessment of Cancer Theranostics Response

> **NIH NIH R44** · AIQ GLOBAL INC · 2024 · $1,104,267

## Abstract

Project Summary
 Theranostics combines molecular targeted diagnostic and therapeutic radionuclides for imaging and ther-
apy in advanced malignancies, with a projected US market of more than $6.7B. Currently, metastatic castra-
tion-resistant prostate cancer (mCRPC) with FDA approved lutetium-177 (177Lu)-based peptide receptor
targeting radionuclide therapy (PRRT), represents the largest market. Prostate specific membrane antigen
(PSMA) is the most commonly used molecular target for combined imaging and treatment of mCRPC. Recent
studies have demonstrated that PSMA PET/CT has high potential to assess tumor PSMA status, treatment
response assessment, and treatment-related toxicities in mCRPC. However, due to the lack of commercial
image analysis software tools, the full potential of theranostic patient imaging is underutilized clinically.
Currently, treating clinicians cannot fully utilize the information provided by molecular images, because
manual image assessment is both laborious and subjective. Currently, there are no tools to combine and
automate (1) cross-modality radiotracer uptake concordance (e.g.PSMA PET/CT vs. CT), (2) assessment of
individual lesion response for all lesions, and (3) early identification of critical organ toxicity, nor can any
compute all three simultaneously, quantitatively, and efficiently. Therefore, it is crucial to have a dedicated
and optimized theranostics tool that provides quantitative information for all three assessments to help
understand the interplay between lesion response, treatment-related toxicities, organ and lesion radiation
dose estimates, target receptor expression, and the impact of each of these factors on predicting patient
outcomes. To meet these challenges, AIQ Solutions proposes to develop a dedicated, AI-powered
theranostics product called TRAQinform Theranostics for theranostic patient management that provides a
comprehensive spatio- temporal analysis of theranostic response including: (1) quantification of target
receptor status on a lesion-by- lesion basis to optimize theranostic patient selection, (2) quantification and
prediction of treatment efficacy, including response of all tumor lesions, and (3) quantification and prediction
of treatment-related toxicities in critical organs.
 Successful development of TRAQinform Theranostics will provide treating clinicians and researchers
with actionable, quantitative, and clinically relevant decision-making data much earlier in the treatment
process, thus improving clinical outcomes, improving quality of life and reducing therapy costs. This novel
software will be integrated into AIQ’s patented, FDA 510(k)-cleared suite of treatment response assessment
software.

## Key facts

- **NIH application ID:** 10933574
- **Project number:** 5R44CA285006-02
- **Recipient organization:** AIQ GLOBAL INC
- **Principal Investigator:** Paul G. Corn
- **Activity code:** R44 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2024
- **Award amount:** $1,104,267
- **Award type:** 5
- **Project period:** 2023-09-22 → 2026-08-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10933574

## Citation

> US National Institutes of Health, RePORTER application 10933574, Comprehensive Assessment of Cancer Theranostics Response (5R44CA285006-02). Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/grant/nih/10933574. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*